biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.
Company profile
Ticker
PHGE, PHGE-UN, PHGEW
Exchange
Website
CEO
Jonathan Eithan Solomon
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Chardan Healthcare Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
BiomX Ltd. • Adaptive Phage Therapeutics, LLC. ...
PHGE stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
15 Apr 24
S-8
Registration of securities for employees
4 Apr 24
10-K
2023 FY
Annual report
4 Apr 24
8-K
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
D
$61.55 mm in equity / options / securities to be acquired, sold $61.55 mm, 34 investors
1 Apr 24
8-K/A
Departure of Directors or Certain Officers
21 Mar 24
8-K
Completion of Acquisition or Disposition of Assets
18 Mar 24
8-K
Form of Parent Stockholder Support Agreement
6 Mar 24
EFFECT
Notice of effectiveness
3 Jan 24
Transcripts
PHGE
Earnings call transcript
2023 Q4
3 Apr 24
PHGE
Earnings call transcript
2023 Q2
9 Aug 23
PHGE
Earnings call transcript
2023 Q1
15 May 23
PHGE
Earnings call transcript
2022 Q4
29 Mar 23
PHGE
Earnings call transcript
2022 Q3
9 Nov 22
PHGE
Earnings call transcript
2022 Q2
11 Aug 22
PHGE
Earnings call transcript
2022 Q1
11 May 22
PHGE
Earnings call transcript
2021 Q4
30 Mar 22
PHGE
Earnings call transcript
2021 Q3
15 Nov 21
PHGE
Earnings call transcript
2021 Q2
16 Aug 21
Latest ownership filings
3
Susan Blum
15 Apr 24
SC 13G/A
Cystic Fibrosis Foundation
26 Mar 24
3
Initial statement of insider ownership
26 Mar 24
SC 13G
AMR Action Fund, L.P.
25 Mar 24
SC 13D
Flynn James E
22 Mar 24
3
JONATHAN S LEFF
21 Mar 24
3
Gregory Louis Merril
21 Mar 24
3
JESSE GOODMAN
21 Mar 24
4
James E Flynn
19 Mar 24
3
James E Flynn
19 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm | 23.39 mm |
Cash burn (monthly) | 2.42 mm | 1.22 mm | 2.63 mm | 2.21 mm | 1.97 mm | 1.85 mm |
Cash used (since last report) | 16.61 mm | 8.36 mm | 18.05 mm | 15.14 mm | 13.53 mm | 12.69 mm |
Cash remaining | 6.78 mm | 15.03 mm | 5.35 mm | 8.25 mm | 9.86 mm | 10.70 mm |
Runway (months of cash) | 2.8 | 12.3 | 2.0 | 3.7 | 5.0 | 5.8 |
Institutional ownership, Q2 2023
29.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 13 |
Increased positions | 1 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 7.93 mm |
Total shares | 16.22 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
John Howard Burbank III | 4.60 mm | $1.26 mm |
OrbiMed Israel BioFund GP Limited Partnership | 4.55 mm | $1.25 mm |
Centaurus Investments | 2.84 mm | $779.00 k |
Cystic Fibrosis Foundation | 2.75 mm | $990.00 k |
TAK Takeda Pharmaceutical | 1.48 mm | $3.65 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | OrbiMed Israel BioFund GP Limited Partnership | Warrants Common Stock | Buy | Acquire P | Yes | No | 0.2311 | 2,163,500 | 499.98 k | 2,163,500 |
15 Mar 24 | OrbiMed Israel BioFund GP Limited Partnership | Series X Preferred Stock Common Stock | Buy | Acquire P | Yes | No | 0 | 4,327 | 0.00 | 4,327 |
15 Mar 24 | Flynn James E | Common Stock | Grant | Acquire A | Yes | No | 0 | 3,055,049 | 0.00 | 3,055,049 |
15 Mar 24 | Flynn James E | Common Stock | Grant | Acquire A | Yes | No | 0 | 3,055,049 | 0.00 | 3,055,049 |
15 Mar 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 0 | 40,350 | 0.00 | 53,840 |
15 Mar 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 0 | 40,350 | 0.00 | 53,840 |
15 Mar 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 0 | 13,490 | 0.00 | 13,490 |
15 Mar 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Grant | Acquire A | Yes | No | 0 | 13,490 | 0.00 | 13,490 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Apr 24
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
24 Apr 24
BiomX Q4 EPS $(0.08) Up From $(0.20) YoY
3 Apr 24
HC Wainwright & Co. Reiterates Buy on BiomX, Maintains $2 Price Target
3 Apr 24
BiomX FY EPS $(0.51) Up From $(0.95) YoY
3 Apr 24
Press releases
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
4 Apr 24
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
3 Apr 24
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
27 Mar 24
BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing
18 Mar 24
Thinking about buying stock in Marpai, Axcelis Technologies, Amylyx Pharmaceuticals, Biomx, or X4 Pharmaceuticals?
11 Mar 24